Akebia Therapeutics (AKBA) shares were down more than 14% in recent Thursday trading after the biopharmaceutical company reported a wider-than-expected Q4 loss.
Earlier, the company reported a Q4 net loss of $0.10 per diluted share. Analysts polled by FactSet expected a loss of $0.08.
Revenue for the quarter ended Dec. 31 was $46.5 million, down from $56.2 million a year earlier. Analysts surveyed by FactSet expected $37.3 million.
The company said it has sufficient funds to run its current operating plan for at least two years.
Price: 1.65, Change: -0.29, Percent Change: -14.77
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。